TickerTalks
Browse all tickers →
TickerTalks›$AGEN
AGAGEN

Agenus Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 40% YoY at strong marginsConsistent chatter on X (2.8K/wk), no spike
$AGEN·$255M·Biotechnology·Healthcare
$5.06+0.9%YTD+57.5%1Y-19.5%
Mentions · last 7 days
2026-07-08: 3 posts2026-07-09: 1 posts2026-07-10: 1 posts2026-07-11: 1 posts2026-07-12: 1 posts2026-07-13: 1,909 posts2026-07-14: 891 posts2,807+27271%
Price updated 14m ago·X counts updated 2d ago
AGAGEN
$AGENAgenus Inc.
$5.06+0.95%2.8k posts+27271%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $AGEN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventCooling offAI verdict · as of 2026-07-15

Catching its breath after a run — could pick back up or fade from here.

Immuno-oncology microcap doubled on a trial pivot, then just took a $340M pill to fund the follow-on — clinical hopes now weighed down by heavy dilution.

Agenus is a clinical-stage immuno-oncology company whose most-watched asset is the botensilimab/balstilimab combination being tested in neoadjuvant microsatellite-stable colon cancer via the ROBBIN study. The stock doubled last week on the pivot to focus resources on ROBBIN, then dropped 17% today when the financing terms landed.

What actually happened:

  • The financing is enormous relative to the company: a Securities Purchase Agreement for 23M shares plus Series A/B warrants that could inject up to $340M — against a pre-deal market cap of roughly $200M, this is on the order of 60%+ dilution on full warrant exercise, priced at $3.69 per share against last week's spike above $5.
  • The dilution is the price of survival: Q1 cash burn ran roughly $36M against fresh cash needs to launch and enroll ROBBIN, so without this raise the runway ran out — the $340M funding envelope is what buys the trial the shot at working.
  • The clinical thesis is why any of this matters: botensilimab plus balstilimab in neoadjuvant MSS colon cancer is a genuine unmet-need pocket where standard immunotherapy has not worked, and a positive ROBBIN readout would re-rate the entire equity by orders of magnitude — that's the outcome the raise is structured to finance.
  • The insider signal is neutral rather than reassuring: CEO Garo Armen received small share awards in early July but no open-market purchases, and the 2019 equity-plan expansion plus an option-exchange program signal the board is repricing underwater comp — a common but not confidence-inspiring pattern.

The next real catalyst is ROBBIN clinical progress reporting or interim data — a signal of activity is what would let the tape absorb the new share count and extend the recovery, while another financing or a trial-timeline slip is what turns today's cooling into a durable fade.

What to watch: Any ROBBIN clinical update or interim readout timeline — a signal of activity is what would let the tape absorb the 23M new shares and extend the recovery. Another financing round or a delayed trial timeline is what confirms today's cooling into a durable fade.

On the calendar: 2026-08-10 — Q2 2026 earnings

no sentiment

Read the AI verdict + X sentiment for $AGEN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage immuno-oncology company developing checkpoint antibodies and cancer immunotherapies via proprietary antibody discovery platforms.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $AGEN.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+47.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
3.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
10.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
6.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-34.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-23.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
52.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 11, 2026$1.02$2.10-51.4%
Q4 2025Mar 16, 2026$0.56$-1.27+144.1%
Q3 2025Nov 10, 2025$1.94$2.63-26.2%
Q2 2025Aug 11, 2025$-1.00$-0.78-28.2%
Next earningsMon, Aug 10·consensus EPS $0.06

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$33.7M+40.2%98.3%44.6%$1.03$-36.0M
Q4 FY25$34.2M+27.5%78.0%42.1%$-0.30$-16.6M
Q3 FY25$30.2M+20.4%19.8%-15.0%$2.00$-14.7M
Q2 FY25$25.7M+9.3%-4.9%-65.0%$-1.00$-20.2M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$136.4M$123.8M – $149.0M$0.79$0.69 – $0.881
FY27$137.9M$125.1M – $150.7M-$0.18-$0.20 – -$0.161
FY28$128.0M$123.0M – $133.0M-$0.56-$0.63 – -$0.492
FY29$137.8M$125.0M – $150.6M-$0.34-$0.38 – -$0.301
FY30$175.8M$159.5M – $192.1M$0.09$0.08 – $0.101

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.38%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+45.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+37.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 37.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today11.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.555-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 25 other (25 awards) in window

See when $AGEN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 138-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Agenus Inc. entered into a Securities Purchase Agreement on July 13, 2026 for a private placement with institutional and accredited investors, closing expected July 15, 2026. The company will issue up to 23,035,227 shares (or pre-funded warrants at $0.01/share exercise price), plus Series A Warrants for ~21.1 million shares at $4.02 and Series B Warrants for ~33.8 million shares at $5.03, all at a combined effective purchase price of $3.69/share. Gross proceeds are approximately $85 million upfront, with up to $255 million more upon full warrant exercise. Highly dilutive capital raise — adds roughly 77 million initial shares and up to 55 million additional on warrant conversion — reflecting significant financing pressure.

8-KMaterial agreementJul 68-K — Item 1.01: Material agreement
AI summary

Agenus Inc. executed an amendment with existing noteholders on June 29, 2026, extending the maturity of $5.09 million in 2015 senior subordinated notes by 8 months to February 18, 2027, and extending the expiration of existing A, B, and C Warrants to June 25, 2031. Additionally, new 2026 D Warrants to purchase 56,525 shares of common stock at $3.25/share (expiring June 25, 2031) were issued to certain noteholders; those shares are to be registered for resale within 90 days. Small-scale debt and warrant management transaction — the 8-month note extension defers a near-term maturity with minimal dilution (~57K new warrants), reflecting Agenus's ongoing capital management.

8-KShareholder voteJun 238-K — Item 5.07: Shareholder vote
AI summary

Agenus Inc. held its 2026 Annual Meeting on June 16, 2026 with 65.24% of shares represented. Shareholders elected Class II directors Garo Armen and Jennifer Buell, approved increases to the ESPP (150K to 200K shares) and 2019 Equity Incentive Plan (+5 million shares), approved a one-time stock option exchange program allowing directors and executives to swap underwater options for new grants with premium strike prices, and ratified KPMG LLP as auditor. The stock option exchange program is the most notable outcome — it effectively reprices executive and director awards, signaling existing strike prices are materially above the current share price.

8-KOfficer or director changeMay 158-K — Item 5.02: Officer or director change
AI summary

Agenus Inc. disclosed on May 15, 2026 that Austin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer of Agenus, resigned effective May 29, 2026. No successor was named in the filing. Routine departure of an accounting officer; watch for a follow-on 8-K naming a replacement PAO and evaluating whether there is broader finance team instability at the company.

SC 13DActivist position (5%+)Jan 23SC 13D
+ 10 other (2 proxys · 2 earnings 8-Ks · 1 10-Q · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivotzacks.com·2d agoAgenus (AGEN) Moves 82.7% Higher: Will This Strength Last?zacks.com·2d agoAgenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcriptseekingalpha.com·3d agoAgenus shares surge as company secures up to $340M to advance colon cancer trialproactiveinvestors.com·3d agoAgenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBINbenzinga.com·3d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$REGN$MRNA$AURA$SLS$ALLO$RXRX
Voices on X · last 7 days

No standout posts about $AGEN on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport